The widening operating loss and binary BLA outcome in Q4 2026 create a high-risk/high-reward setup. Monitor for any FDA feedback or advisory committee announcements ahead of the BLA submission, as well as enrollment updates from the AURORA NSCLC trial. The $201.6M cash runway into Q1 2028 provides a long no-dilution window, but the stock will likely trade on pipeline catalysts rather than quarterly financials.
Price Chart
Executive Summary
Candel Therapeutics reported Q2 2026 financial results with a net loss of $38.9M ($0.52/share), significantly wider than the $4.8M loss in Q2 2025, driven by a $12.3M non-cash charge from warrant liability revaluation and higher R&D spend ($19.8M vs $7.0M). The clinical-stage biotech has no revenue and remains on track for a Q4 2026 BLA submission for aglatimagene in prostate cancer, with a strong cash position of $201.6M funding operations into Q1 2028. The Lancet Oncology publication of positive phase 3 data and activation of the AURORA NSCLC phase 3 trial are key pipeline catalysts, but the widening operating loss and lack of near-term revenue keep the stock in a binary event-driven pattern ahead of the BLA submission.
Key Financial Metrics
Key Facts
- Net loss of $38.9M in Q2 2026 vs $4.8M loss in Q2 2025, primarily due to a $12.3M non-cash charge from change in fair value of warrant liabilities
- R&D expenses rose to $19.8M from $7.0M year-over-year, driven by clinical trial and manufacturing costs for aglatimagene programs
- Cash and cash equivalents of $201.6M as of June 30, 2026, expected to fund operations into Q1 2028
- Pivotal phase 3 data for aglatimagene in localized prostate cancer published in The Lancet Oncology, showing 39% improvement in PCa-specific DFS
- First trial site activated for the global pivotal phase 3 AURORA trial of aglatimagene in NSCLC
- BLA submission for aglatimagene in prostate cancer planned for Q4 2026
- Appointed Mark Sims as Chief Commercial Officer to support potential 2027 launch
Financial Impact
Net loss widened to $38.9M in Q2 2026 from $4.8M in Q2 2025; operating loss grew to $26.7M from $11.2M; cash burn rate increased significantly
Risk Factors
- BLA submission delay or negative FDA feedback on aglatimagene in prostate cancer
- Further dilution risk if cash burn accelerates beyond current runway projections
- Clinical trial failure in the AURORA NSCLC phase 3 study
- Warrant liability revaluation could continue to cause volatile GAAP earnings swings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-347957 |
| Document: cadl-20260813.htm | 0001193125-26-347957 |
| Document: 0001193125-26-347957-index-headers.html | 0001193125-26-347957 |
| Document: 0001193125-26-347957-index.html | 0001193125-26-347957 |
| Document: 0001193125-26-347957.txt | 0001193125-26-347957 |
| 8-K Data (Synthetic) | 0001193125-26-347957 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | Press Release | $10.16 | awaiting T+60 | — | $8.25 (−18.80%) |
Sep 30, 2026 27d ago | Press Release | $10.44 | awaiting T+60 | — | $8.25 (−20.98%) |
Sep 10, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $8.25 (−27.18%) |
Sep 9, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $8.25 (−27.18%) |
Aug 15, 2026 10w ago | Institutional Cluster | $12.16 | awaiting T+60 | — | $8.25 (−32.15%) |
Aug 13, 2026 10w ago | 8-K | $11.80 | awaiting T+60 | — | $8.25 (−30.08%) |
Aug 13, 2026 10w ago | Press Release | $11.80 | awaiting T+60 | — | $8.25 (−30.08%) |
Aug 3, 2026 12w ago | Press Release | $10.07 $8.16 | ▼ −18.97% | ▼ −20.75% | $8.25 (−18.07%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $8.25 (−16.07%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $8.25 (−16.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers